<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729155</url>
  </required_header>
  <id_info>
    <org_study_id>PMK-SCRIP-CIN</org_study_id>
    <nct_id>NCT02729155</nct_id>
  </id_info>
  <brief_title>Single-cycle Remote Ischemic Preconditioning and Postconditioning for Prevention of Contrast-Induced Nephropathy (SCRIP-CIN) Trial</brief_title>
  <official_title>Efficacy of Single-cycle Remote Ischemic Pre/Post-conditioning, for Prevention of Contrast-induced Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Coronary Angiography or Coronary Angioplasty at Phramongkutklao Hospital and Thammasat Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a 2 x 2 factorial design, double-blinded, randomized controlled trial to
      evaluate efficacy and safety of remote ischemic preconditioning and postconditioning for
      prevention of contrast-induced acute kidney injury in patient undergoing coronary angiography
      and angioplasty
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CI-AKI, which was defined as an increment of serum creatinine 0.5 mg/dL or a relative increase of 25% over the baseline value</measure>
    <time_frame>Within a period of 24 hours after contrast medium administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sCr and eGFR from baseline</measure>
    <time_frame>Within a period of 24 hours after contrast medium administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cerebrovascular and cardiovascular events (MACCE) in each intervention group</measure>
    <time_frame>Within a period of 6 months after contrast medium administration</time_frame>
    <description>MACCE were composite of death, hospitalization, acute coronary syndrome, congestive heart failure and stroke or transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence(%) of CI-AKI in differrent subgroups of patient characteristics</measure>
    <time_frame>Within a period of 24 hours after contrast medium administration</time_frame>
    <description>Patient characteristics include eGFR, global CIAKI risk score, contrast media volume and DM.
Incidence of CI-AKI, which was defined as an increment of serum creatinine 0.5 mg/dL or a relative increase of 25% over the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence(%) of CI-AKI in patients with vs without RIPre and RIPost</measure>
    <time_frame>Within a period of 24 hours after contrast medium administration</time_frame>
    <description>Incidence of CI-AKI, which was defined as an increment of serum creatinine 0.5 mg/dL or a relative increase of 25% over the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence(%) of MACCE in differrent subgroups of patient characteristics</measure>
    <time_frame>Within a period of 6 months after contrast medium administration</time_frame>
    <description>Patient characteristics include eGFR, global CIAKI risk score, contrast media volume and DM.
MACCE were composite of death, hospitalization, acute coronary syndrome, congestive heart failure and stroke or transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence(%) of MACCE in patients with vs without RIPre and RIPost</measure>
    <time_frame>Within a period of 6 months after contrast medium administration</time_frame>
    <description>Patient characteristics include eGFR, global CIAKI risk score, contrast media volume and DM.
MACCE were composite of death, hospitalization, acute coronary syndrome, congestive heart failure and stroke or transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence(%) of MACCE in patients who have CI-AKI vs patients who have no CI-AKI</measure>
    <time_frame>Within a period of 6 months after contrast medium administration</time_frame>
    <description>Incidence of CI-AKI, which was defined as an increment of serum creatinine 0.5 mg/dL or a relative increase of 25% over the baseline value within a period of 24 hours after contrast medium administration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">596</enrollment>
  <condition>Ischemic Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>RIPre + RIPost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: RIPre 200 mmHg + RIPost 200 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIPre + Sham</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: RIPre 200 mmHg + Sham 10 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + RIPost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Sham 10 mmHg + RIPost 200 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intervention: Sham 10 mmHg + Sham 10 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIPre</intervention_name>
    <description>Preconditioning 200 mmHg x 5 minutes before procedure</description>
    <arm_group_label>RIPre + RIPost</arm_group_label>
    <arm_group_label>RIPre + Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIPost</intervention_name>
    <description>Postconditioning 200 mmHg x 5 minutes after procedure</description>
    <arm_group_label>RIPre + RIPost</arm_group_label>
    <arm_group_label>Sham + RIPost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham-Pre</intervention_name>
    <description>Sham 10 mmHg x 5 minutes before procedure</description>
    <arm_group_label>Sham + RIPost</arm_group_label>
    <arm_group_label>Sham + Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham-Post</intervention_name>
    <description>Sham 10 mmHg x 5 minutes after procedure</description>
    <arm_group_label>RIPre + Sham</arm_group_label>
    <arm_group_label>Sham + Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient have indication for coronary angiography or angioplasty.

          -  Impaired renal function with reduced eGFR &lt; 60 ml/min/1.73 m2 by CKD-EPI equation.

          -  Written informed consent.

        Exclusion Criteria:

          -  History of contrast allergy.

          -  The patient had end-stage renal failure with the need for hemodialysis.

          -  The patient take medications that affect the kidneys function within 48 hours before
             study.

          -  The patient had acute kidney injury from any cause.

          -  The patient was received contrast media within 2 weeks before study.

          -  The patient had cardiac arrest or shock.

          -  The patient had peripheral arterial disease (PAD)

          -  Pregnancy

          -  Refused to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nakarin Sansanayudh, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phramongkutklao College of Medicine and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nakarin Sansanayudh, MD,PhD</last_name>
    <phone>+6627639300</phone>
    <phone_ext>93807</phone_ext>
    <email>dr_nakarin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pawit Pipatwattanakul, MD</last_name>
    <phone>+6613728821</phone>
    <email>pa_wit@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nakarin Sansanayudh, MD,PhD</last_name>
      <phone>+6623547600</phone>
      <phone_ext>93827</phone_ext>
      <email>dr_nakarin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pawit Pipatwattanakul, MD</last_name>
      <phone>+6613728821</phone>
      <email>pa_wit@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phramongkutklao College of Medicine and Hospital</investigator_affiliation>
    <investigator_full_name>Col. Suthee Panichkul</investigator_full_name>
    <investigator_title>Phramongkutklao College of Medicine and Hospital</investigator_title>
  </responsible_party>
  <keyword>Ischemic Preconditioning</keyword>
  <keyword>Postconditioning</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Angiography</keyword>
  <keyword>Contrast-Induced Nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

